P2Y receptors (P2YRs), a family of purinergic G-protein-coupled receptors (GPCRs), are activated by extracellular nucleotides. There are a total of eight distinct functional P2YRs expressed in human, which are subdivided into P2Y 1 -like receptors and P2Y 12 -like receptors 1 . Their ligands are generally charged molecules with relatively low bioavailability and stability in vivo 2 , which limits our understanding of this receptor family. P2Y 12 R regulates platelet activation and thrombus formation 3, 4 , and several antithrombotic drugs targeting P2Y 12 R-including the prodrugs clopidogrel (Plavix) and prasugrel (Effient) that are metabolized and bind covalently, and the nucleoside analogue ticagrelor (Brilinta) that acts directly on the receptor-have been approved for the prevention of stroke and myocardial infarction. However, limitations of these drugs (for example, a very long half-life of clopidogrel action and a characteristic adverse effect profile of ticagrelor) 5, 6 suggest that there is an unfulfilled medical need for developing a new generation of P2Y 12 R inhibitors 7, 8 . Here we report the 2.6 Å resolution crystal structure of human P2Y 12 R in complex with a non-nucleotide reversible antagonist, AZD1283. The structure reveals a distinct straight conformation of helix V, which sets P2Y 12 R apart from all other known class A GPCR structures. With AZD1283 bound, the highly conserved disulphide bridge in GPCRs between helix III and extracellular loop 2 is not observed and appears to be dynamic. Along with the details of the AZD1283-binding site, analysis of the extracellular interface reveals an adjacent ligand-binding region and suggests that both pockets could be required for dinucleotide binding. The structure provides essential insights for the development of improved P2Y 12 R ligands and allosteric modulators as drug candidates.
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P2Y 12 R, a member of the P2Y purinergic GPCR family stimulated by adenosine diphosphate (ADP), is a major player in platelet aggregation and granule secretion and supports the formation of a thrombus 9 . Ethyl 6-(4-((benzylsulphonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) (Extended Data Fig. 1 ) was recently revealed by AstraZeneca as a novel P2Y 12 R antagonist for the treatment of arterial thrombosis. AZD1283 efficiently inhibits platelet activation in vivo with only a limited increase in the bleeding time 10 .
To understand how antithrombotic drugs recognize their purinoceptor target, we solved the structure of an engineered human P2Y 12 R by inserting a thermostabilized apocytochrome, b 562 RIL (BRIL), in the third intracellular loop (ICL3) 11 in complex with AZD1283 at 2.6 Å (Extended Data Table 1 ). A point mutation-D294 xxY motif of helix VII was introduced to improve the purified protein yield twofold (Extended Data Fig. 2 ). Saturation and competition binding assays indicate that neither the BRIL fusion nor the point mutation significantly influenced ligand binding of P2Y 12 R (Extended Data Table 2 ).
The overall fold of the P2Y 12 R structure consists of a canonical seven transmembrane (7TM) bundle of a-helices and a carboxy-terminal helix VIII that is parallel to the membrane bilayer (Fig. 1a) . Several loops, especially ECL2, appear to be flexible and result in a total of 24 ). Two receptor molecules from adjacent unit cells form receptor-receptor interactions in a parallel orientation mediated by helix V. Two cholesterol molecules are observed bound to each receptor: one is at the interface of helices III and V, stabilizing the receptor-receptor interaction, and the other is at the interface of helices I and VII and does not participate in crystal contacts (Extended Data Fig. 3) .
The P2Y 12 R structure has important features that set it apart from another representative of the d group of class A GPCRs 13 , protease activated receptor 1 (PAR1, ,24% sequence identity; transmembrane C a root mean squared deviation (r.m.s.d.) ,2.2 Å ), and other known class A structures, such as the b 2 -adrenergic receptor (b 2 AR, transmembrane C a r.m.s.d. 2.6-3.5 Å ) (Fig. 1b-d) . Whereas helix V in most of the class A GPCR structures that have been determined so far is bulged and bent at a highly conserved P 5.50 , P2Y 12 R has N201
5.50 (and V 5.50 for the other P2Y 12 R-like receptors, P2Y 13 R and P2Y 14 R), and, consequently, its structure lacks the corresponding helical bend. Moreover, P2Y 12 R has no other proline or glycine residues in helix V that could destabilize its straight a-helical conformation. Besides P2Y 12 R, the only other receptor structure solved so far that also lacks the conserved proline and corresponding bend in helix V is the sphingosine 1-phosphate receptor 1 (S1P 1 ) 14 . However, compared with S1P 1 , helix V of P2Y 12 R extends ,2 additional helical turns above the extracellular side of the membrane, and thus is also ,1-2 helical turns longer than in other known GPCR structures. The unique straightening and elongation of helix V observed in the P2Y 12 R structure results in a shift of its extracellular end towards helix IV by more than 6 Å in comparison with other known class A structures, leading to rearrangements in other helices and extracellular loops.
Other distinct conformational features of the P2Y 12 R structure are observed in helices VII and VI. The intracellular tip of helix VII is closer to the axis of the 7TM bundle than in most class A GPCR structures, in an 'inward' position similar to PAR1 (ref. 15) . The helix VI intracellular tip is shifted slightly outward, and the whole helix VI is translated along its axis towards the intracellular surface by a half a-helical turn as compared with other known GPCR structures (Fig. 1d and Extended Data Fig. 4d ). Owing to this shift, the conserved R122 3.50 in the D(E)R 3.50 Y motif, which forms an ionic or a hydrogen-bonding lock with E 6.30 or T 6.34 in rhodopsin and several other GPCRs, is actually located at the same level as a hydrophobic side-chain V238 6 .37 in the P2Y 12 R structure (Extended Data Fig. 4a-c ). This residue arrangement excludes formation of an ionic lock or polar interaction between helix VI and the DRY motif. The lack of an ionic lock or a polar interaction between helix VI and the DRY motif, as well as active-like conformations of the intracellular side of helices VI and VII, suggest that P2Y 12 R might be more prone to activation, in agreement with previous reports that this receptor exhibits high levels of basal activity 16, 17 . Another key structural difference in helix VI occurs in the centre of the 7TM helical bundle at position 6.48, which in many class A GPCRs contains a tryptophan residue, involved in ligand binding and implicated in signal transduction 18 . In all P2YRs and PARs, however, W 6.48 is replaced with F(Y) 6.48 , which displays the same orientation in both structures that might be a common feature within the d group (Extended Data Fig. 4e ).
AZD1283 binds to P2Y 12 R in a pocket that is very distinct in location and shape from that seen in previously solved GPCRs (Fig. 2) . The elongated ligand stretches over more than 17 Å between helices IV and VII, making a number of polar and hydrophobic interactions with side chains from helices III-VII (Fig. 2a, b ). The orientation of this ligand is orthogonal to a general ligand position in solved receptor complexes from a, b and c groups in class A GPCRs, although it shares some similarity with the orientation of vorapaxar in PAR1, which belongs to the d group (Extended Data Fig. 4 ). The piperidinyl-nicotinate group of the antagonist inserts into a sub-pocket formed by helices III, IV and V, whereas the benzylsulphonyl group mainly interacts with helices VI and VII. The structure reveals at least seven polar and ionic interactions between P2Y 12 R and AZD1283 (Fig. 2b) . Additionally, the benzene ring of Y105 3.33 forms a p-p interaction with the nicotinate and a hydrophobic interaction with the piperidine group, and the phenyl group of the ligand inserts into a hydrophobic pocket formed by the side chains of F252 6 .51 , R256 6 .55 , Y259 6.58 , L276 7.31 and K280 7.35 . Although the AZD1283-binding pocket of P2Y 12 R and its equivalent in PAR1 are formed by the same helices, there are significant differences between them. Whereas in PAR1, 24 residues of ECL2 cover the entire 
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binding pocket and participate in extensive ligand interactions, the unresolved 16 residues of ECL2 in P2Y 12 R are likely to be more flexible and to have a lesser role in interactions with AZD1283. Moreover, the extracellular ends of helices IV, VI and VII in P2Y 12 R are shifted outwards compared with PAR1, making the ligand-binding pocket of P2Y 12 R more open and allowing AZD1283 to bind deeper in the 7TM domain (Fig. 2c, d ). Within the P2Y 12 R extracellular cavity formed by all 7TM helices, two residues, Y105 3.33 and K280 7.35 , form a barrier separating the cavity into two pockets. Pocket 1 is composed of helices III-VII, forming the binding site of AZD1283, whereas pocket 2 consists of helices I-III and VII and is not occupied in the structure (Fig. 2e) .
Two cysteine residues in helix III and ECL2 (C97 3.25 and C175 in P2Y 12 R) are highly conserved throughout the GPCR superfamily 19 , and, when present, they are observed to form a disulphide bond in all the GPCR structures solved so far 20, 21 . To our knowledge, the only receptor structure that lacks the conserved Cys 3.25 and the corresponding disulphide bridge is S1P 1 (ref. 14) , and it also lacks any secondary structure in ECL2. In the crystal structure of P2Y 12 R, no electron density is observed for most of ECL2 or for a potential disulphide bond at C97, suggesting the possibility of a labile or dynamic disulphide bond in P2Y 12 R, a feature that would be different from other known GPCRs and may be important functionally. Consistent with the labile nature of a disulphide in the structure, C97 3.25 A and C175A mutations retain similar protein yield and stability, with no obvious aggregation, according to analytical size-exclusion chromatography (aSEC) (Extended Data  Fig. 5c ). In addition, the melting temperatures of both mutants are substantially higher in complex with AZD1283 than in the apo form and are equivalent to that of the native constructs (Extended Data Fig. 5f ), suggesting that neither the receptor's conformation nor its ability to bind AZD1283 is affected by the cysteine mutations. On the contrary, alanine mutations of C17 or C270 7.25 , which disrupt the disulphide bond that is clearly observed in the structure, lead to a marked receptor aggregation (Extended Data Fig. 5d ). These data suggest that the disulphide bridge between ECL2 and helix III may be labile in native P2Y 12 R, thus leaving C97 3.25 and C175 available for interactions with the thiol moieties of drug metabolites.
Residue C97 3.25 has been previously implicated by functional assays as a covalent binding site for the active metabolites of P2Y 12 R drugs 8, 22 . Our aSEC results are consistent with C97 3.25 being the primary attachment site for the active metabolite of prasugrel, R-138727 (Extended Data Fig. 5e ). The suggestion of a dynamic disulphide bridge in our structure correlates with the previous observation that thiol-reactive reagents such as p-chloromercuribenzene sulphonate (pCMBS) specifically inhibit activation of P2Y 12 R but not other receptors such as P2Y 1 R 23 . In addition, these observations are consistent with the absolute selectivity of the active metabolites of prasugrel and clopidogrel for the P2Y 12 R; so far, there have been no reports that they exhibit detectable binding to any other receptor. The structure of P2Y 12 R opens up more possibilities to explain these previous observations, but additional evidence is needed to fully understand their mechanisms.
As residue C97 3.25 belongs to pocket 2 in the AZD1283-bound P2Y 12 R, the active metabolites of drugs that covalently link to this residue may occupy pocket 2 as well. This is consistent with the docking analysis, from which pocket 2 seems to be an energetically favourable binding site for these active metabolites (Fig. 3a, b) . However, docking of nucleotide agonists into the crystal structure of antagonistbound P2Y 12 is less definitive, which probably reflects high conformational plasticity of the ligand-binding region in this receptor. Although limited mutagenesis data are consistent with binding of the nucleotides in pocket 2, docking allows for 2-methylthio-adenosine 59-diphosphate (2MeSADP) binding in either pocket (Extended Data  Fig. 6 ). Mutations of a few residues that belong to pocket 2, K80 2.60 A or E281 7.36 A, or a residue at the interface of the two pockets, K280 7.35 A, decrease the binding affinity of the nucleotide radioligand [ Table 3 and Extended Data Fig. 7) . In both docking models, R256 6.55 , which was previously reported to be important for the activation of P2Y 12 R 24, 25 , potentially makes contact with the phosphate groups of 2MeSADP. This is consistent with pharmacological and biochemical data showing that mutations of this residue affect both the number of binding sites and their affinities for radio-labelled 2MeSADP in patient platelets and in transfected CHO cells [26] [27] [28] . Another residue, R265
ECL3
, which was previously reported to affect P2Y 12 
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2MeSADP; the effect of mutations in R265 ECL3 impairing receptor activation is probably due to their effects on the conformational states of the receptor, rather than on agonist binding. Dinucleotide recognition at P2YRs is dependent on an optimal polyphosphate chain length and on precise substituents of both nucleoside moieties, suggesting that both pockets of the extended binding site participate in recognition. This is also consistent with dinucleotide docking to the AZD1283-bound P2Y 12 R structure, in which one nucleotide may bind in pocket 1 while the second half of the dinucleotide molecule is predicted to wrap around helix III to reach pocket 2, and the polyphosphate moiety occupies a highly cationic region of the binding site (Fig. 3c, d) . The possibility of multiple binding pockets in the P2Y 12 R structure extends our knowledge of purinoceptor family ligand recognition mechanisms, and will serve as a template for designing improved orthosteric and allosteric drug candidates. The high conformational flexibility of the extracellular region suggests the potential for large conformational changes on nucleotide binding and activation, the understanding of which requires further structural studies of P2Y 12 R agonist complexes.
METHODS SUMMARY
The human P2Y 12 R-BRIL fusion protein was expressed in Sf9 insect cells and purified by metal affinity chromatography. P2Y 12 R-BRIL crystals were grown using a lipidic cubic phase (LCP) crystallization method. Diffraction data were collected from 15 crystals on the 23ID-B/D beamline (GM/CA CAT) at the Advanced Photon Source using a 10 mm minibeam at a wavelength of 1.0330 Å . The structure was solved by molecular replacement using the receptor portion of PAR1 (Protein Data Bank (PDB) accession 3VW7) and BRIL (PDB accession 1M6T) as initial models. The Schrödinger suite was used for docking, and saturation and competition assays were performed on cell membranes using [ Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
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METHODS
Protein engineering for structural studies. Human wild-type P2Y 12 R DNA (HUGO Gene Nomenclature Committee (HGNC) accession 18124) was codon optimized and synthesized by Genewiz for insect cell expression, and cloned into a modified pFastBac1 vector (Invitrogen) containing an expression cassette with a haemagglutinin (HA) signal sequence followed by a Flag tag at the N terminus and a PreScission protease site followed by a 103His tag at the C terminus. To facilitate crystallogenesis, thermostabilized BRIL (PDB accession 1M6T) was fused into ICL3 of P2Y 12 R (T223-R224) with intact N and C termini excluding the start codon. The P2Y 12 R-BRIL gene was further modified by introducing the D294 7.49 N mutation based on the sequence alignment of conserved motifs. Expression and purification of Sf9-expressed P2Y 12 R constructs for crystallization. High-titre recombinant baculovirus (.10 8 viral particles per ml) was obtained using the Bac-to-Bac Baculovirus Expression System (Invitrogen). Sf9 cells at a cell density of 2-3 3 10 6 cells ml 21 were infected with virus at a multiplicity of infection (m.o.i.) of 5. Cells were harvested by centrifugation at 48 h postinfection and stored at 280 uC until use. Insect cell membranes were disrupted by thawing frozen cell pellets in a hypotonic buffer containing 10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl and protease inhibitor cocktail (Roche) with the ratio of 1 tablet per 100 ml lysis buffer. Extensive washing of the raw membranes was performed by repeated centrifugation in the same buffer and then in a high salt buffer containing 50 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl and 1 M NaCl (three times each).
Purified membranes were thawed on ice in the presence of 200 mM AZD1283, 2 mg ml 21 iodoacetamide, and EDTA-free protease inhibitor cocktail (Roche), and incubated at 4 uC for 30 min before solubilization. P2Y 12 R-BRIL was extracted from the membrane by adding n-dodecyl-b-D-maltopyranoside (DDM; Affymetrix) and cholesteryl hemisuccinate (CHS; Sigma) to the membrane solution to a final concentration of 0.5% (w/v) and 0.1% (w/v), respectively, and stirring was continued at 4 uC for 2.5 h. The supernatant was isolated by centrifugation at 160,000g for 30 min and incubated with TALON IMAC resin (Clontech) overnight at 4 uC. The resin was then washed with twenty column volumes of 50 mM HEPES, pH 7.5, 1 M NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS and 20 mM imidazole. The protein was then eluted with 5 column volumes of 50 mM HEPES, pH 7.5, 1 M NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 300 mM imidazole and 200 mM AZD1283. A PD MiniTrap G-25 column (GE Healthcare) was used to remove imidazole. The protein was then treated overnight with Histagged PreScission protease (20 mg per 500 ml of expressed material) and His-tagged PNGase F (20 mg per 500 ml of expressed material) to remove the C-terminal His tag and deglycosylate the receptor. PreScission protease, PNGase F and the cleaved 103His tag were removed from the sample by passing the sample over Ni-NTA superflow resin (Qiagen). The receptor was then concentrated to 20-30 mg ml 21 with a 100 kDa molecular weight cut-off concentrator (Millipore). Protein purity and monodispersity was tested by SDS-PAGE and aSEC. Typically, the protein purity exceeded 95% and the aSEC profile showed a single peak, indicative of receptor monodispersity.
For aSEC analysis of P2Y 12 R in complex with R-138727 (Alsachim), the receptor was first treated with 100 mM R-138727 on insect cell membrane at 4 uC for 1 h and then purified under a similar protocol without further supplement with ligand thereafter. Lipidic cubic phase crystallization of P2Y 12 R. The P2Y 12 R-BRIL construct was crystallized using the lipidic cubic phase (LCP) method by mixing 40% of ,40 mg ml 21 protein with 60% lipid (monoolein and cholesterol 10:1 by mass) using a syringe lipid mixer as described previously 30 . After a clear LCP formed, the mixture was dispensed onto glass sandwich plates (Shanghai FAstal BioTech) into 40 nl drops and overlaid with 800 nl precipitant solution using a Mosquito LCP robot (TTP LabTech). Crystals appeared after 3 days and reached their full size within 2 weeks in 0.05-0.15 M ammonium formate, 0.1 M sodium cacodylate, pH 6.0-6.5, 25-35% PEG400 and 200 mM AZD1283. Crystals were harvested directly from LCP using 100-150 mm micro-loops (M2-L19-100/150, MiTeGen) and flash frozen in liquid nitrogen. Data collection and structure solution. X-ray data were collected on the 23ID-B/ D beamline (GM/CA CAT) at the Advanced Photon Source using a 10 mm minibeam (at a wavelength of 1.0330 Å ) and a MarMosaic 300 CCD detector. Among the crystal samples screened, most crystals diffracted to 3.0-2.6 Å resolution when exposed to 1 s of unattenuated beam using 1u oscillation. Data from the 15 bestdiffracting crystals were integrated and scaled to an overall 2.6 Å resolution using HKL2000 31 . Initial phase information was obtained by molecular replacement using the receptor portion of PAR1 (PDB accession 3VW7) and BRIL (PDB accession 1M6T) independently with the program Phaser 32 . All refinements were performed with Refmac5 33 and Buster 34 followed by manual examination and rebuilding of the refined coordinates in the program Coot 35 using both 2mF o 2 DF c and mF o 2 DF c maps.
Ligand-binding assays. Wild-type and mutant P2Y 12 R plasmids with single amino acid substitutions (Extended Data Table 3 ) were cloned into PCDNA3.0 and transfected into COS7 cells using Lipofectamine 2000 (Life Technologies). Sf 9 cells were harvested 48 h after transfection. After harvesting, cells were homogenized for 15 s and then centrifuged for 10 min at 1,000g. The suspension was re-centrifuged at 20,000g for 60 min. The resulting pellet was re-suspended, homogenized, split into aliquots and maintained at 280 uC in a freezer until use. Protein concentrations were measured using Bio-Rad protein assay reagents. Membranes for binding with the constructs containing BRIL and the point mutation (Extended Data Table 2) were prepared following the same procedure using Sf9 cells.
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